In-transit extremity melanoma III. Homo sapiens

An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with melphalan in the setting of isolated limb infusion or isolated limb perfusion. Gene expression profiles were obtained from 21 lesions across 19 patients and evaluated for expression that correlated with response to melphalan isolated limb infusion. Overall design: Chemotherapy response analysis: complete response - CR; partial response - PR; stable disease - SD; progressive disease - PD; not evaluable - n.e.

本数据集针对接受美法仑（melphalan）行隔离肢体输注（isolated limb infusion）或隔离肢体灌注（isolated limb perfusion）治疗的肢体移行性黑色素瘤（in-transit extremity melanoma）患者的活检样本开展评估。研究从19例患者的21个病灶中获取基因表达谱（gene expression profiles），并评估其与美法仑隔离肢体输注治疗响应的相关性。总体研究设计：化疗疗效响应分为完全缓解（Complete Response, CR）、部分缓解（Partial Response, PR）、疾病稳定（Stable Disease, SD）、疾病进展（Progressive Disease, PD）及不可评估（n.e.）。